Stocks and Investing
Stocks and Investing
Wed, September 25, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jason McCarthy Maintained (CAPR) at Strong Buy with Increased Target to $25 on, Sep 25th, 2024
Jason McCarthy of Maxim Group, Maintained "Capricor Therapeutics, Inc." (CAPR) at Strong Buy with Increased Target from $12 to $25 on, Sep 25th, 2024.
Jason has made no other calls on CAPR in the last 4 months.
There are 2 other peers that have a rating on CAPR. Out of the 2 peers that are also analyzing CAPR, 0 agree with Jason's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Jason
- Joseph Pantginis of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $40 on, Tuesday, September 24th, 2024
- Kristen Kluska of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $8 on, Friday, September 20th, 2024
Contributing Sources